ArticleNPJ primary care respiratory medicine2022
Validation of the Spanish language version of the control of allergic rhinitis and asthma test.
Article in NPJ primary care respiratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis and asthma are common diseases that frequently coexist, referred to as unified airway disease. There is currently no validated scale in Spanish, which allows simultaneous evaluation of both conditions. A translation from Portuguese to Spanish was therefore performed. It was administered to 120 patients aged between 18 and 70 years whose native language was Spanish and presented a diagnosis of allergic rhinitis and asthma. The reliability, validity and sensitivity to instrument change validations were carried out, as well as the values of minimally relevant clinical differences. Reliability was evaluated using Cronbach´s alpha test on CARAT-global: 0.83 [IC 95% 0.79-0.88]; test and retest evaluation was done with Pearson´s correlation coefficient: 0.6 [IC 95% 0.32-0.77] and the standard error of measurement 3.5 (p < 0.005). A confirmatory factor analysis was performed corroborating two factors. Correlation coefficients were not high in the longitudinal validation. Concurrent validity showed an acceptable correlation between CARAT10 asthma ACQ5 and low between allergic rhinitis-VAS. There was a milestone of the controlled disease in the discriminant validity of CARAT10 rhinitis ≥ 8 mean an adequate control, CARAT10-asthma > 16 In this case, CARAT10-asthma value < 16 are interpreted as an inadequate or partial control and values ≥ 16 mean an adequate control and CARAT10-global ≥ 18, patients evaluated with CARAT10 with a result ≥ 18, which would be a patient with both conditions controlled. The minimally relevant clinically important average difference found in the CARAT10 scale was 3.25 (SD 3.77). The CARAT10 scale in Spanish is a standardised, reliable and valid evaluation method on patients with unified airway disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.